Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
$2K Sell
1,300
-176,000
-99% -$74K ﹤0.01% 1884
2023
Q4
$76K Buy
177,300
+38,700
+28% +$31K 0.01% 1195
2023
Q3
$45K Buy
138,600
+17,800
+15% +$34K ﹤0.01% 1562
2023
Q2
$11K Buy
120,800
+69,600
+136% -$10K ﹤0.01% 2205
2023
Q1
$21K Sell
51,200
-238,900
-82% -$253K ﹤0.01% 1899
2022
Q4
$274K Buy
290,100
+46,700
+19% +$2.24M 0.02% 652
2022
Q3
$99K Sell
243,400
-52,900
-18% -$2.57M 0.01% 1396
2022
Q2
$653K Sell
296,300
-346,400
-54% -$252K 0.05% 451
2022
Q1
$905K Sell
642,700
-268,200
-29% -$13.9M 0.05% 419
2021
Q4
$5.1M Sell
910,900
-364,500
-29% -$18.1M 0.21% 90
2021
Q3
$805K Buy
1,275,400
+1,020,800
+401% +$434K 0.04% 555
2021
Q2
$371K Sell
254,600
-61,600
-19% -$2.4M 0.02% 916
2021
Q1
$150K Sell
316,200
-337,200
-52% -$187K 0.01% 1464
2020
Q4
$337K Buy
653,400
+397,000
+155% +$212K 0.02% 814
2020
Q3
$125K Buy
256,400
+64,900
+34% +$66K 0.01% 1184
2020
Q2
$59K Buy
191,500
+85,600
+81% -$3K ﹤0.01% 1639
2020
Q1
$62K Buy
+105,900
New +$62K ﹤0.01% 1603
2019
Q4
– Sell
-4,400
Closed -$1K – 4450
2019
Q3
$1K Buy
+4,400
New +$1K ﹤0.01% 3796
2019
Q1
– Sell
-20,000
Closed -$40K – 4575
2018
Q4
$40K Sell
20,000
-173,200
-90% -$7.58M ﹤0.01% 1625
2018
Q3
$806K Buy
193,200
+133,200
+222% +$5.4M 0.06% 328
2018
Q2
$16K Sell
60,000
-52,000
-46% +$11K ﹤0.01% 2349
2018
Q1
$5K Buy
112,000
+24,900
+29% -$8K ﹤0.01% 3298
2017
Q4
$13K Buy
87,100
+1,400
+2% +$50.3K ﹤0.01% 2929
2017
Q3
$45K Sell
85,700
-105,400
-55% -$64K ﹤0.01% 2336
2017
Q2
$109K Sell
191,100
-52,500
-22% -$65K ﹤0.01% 1785
2017
Q1
$174K Sell
243,600
-190,400
-44% +$2K 0.01% 1291
2016
Q4
$172K Buy
434,000
+300
+0.1% +$9.7K 0.01% 1420
2016
Q3
$407K Buy
433,700
+41,400
+11% +$1.46M 0.02% 714
2016
Q2
$911K Buy
392,300
+163,900
+72% +$5.51M 0.05% 316
2016
Q1
$212K Sell
228,400
-28,100
-11% -$846K 0.01% 980
2015
Q4
$432K Hold
256,500
– – 0.02% 697

Other funds holding PFE

Cutler Group's PFE Position: Q1 2024 in Review

Cutler Group reduced its Pfizer (PFE) stake by 92% in Q1 2024, selling an estimated $3.36M and leaving 10,075 shares worth $279K. The position accounts for 0.09% of the portfolio, ranked #216.

Cutler Group first reported a position in PFE in Q4 2015 and has held it in 33 quarters since. The position peaked at $10.8M in Q1 2022. 2,876 funds tracked by Wall St. Rank hold PFE as of Q1 2024.

  • Cutler Group held 10,075 shares of Pfizer worth $279K as of Q1 2024.
  • Cutler Group sold 120,937 Pfizer shares in Q1 2024, an estimated $3.36M.
  • Pfizer made up 0.09% of Cutler Group's portfolio in Q1 2024, its #216 holding.
  • Cutler Group first reported a position in Pfizer in Q4 2015 and has held it in 33 quarters since.
  • Cutler Group's Pfizer position peaked at $10.8M in Q1 2022.
  • 2,876 funds tracked by Wall St. Rank held Pfizer as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.